Northampton General Hospital N H S Trust
Radium-223 therapy for bone metastasis from prostate cancer
This is a contract result notice, not an open opportunity. Details from the official award data.
This sits in the upper-middle of the Health & Social Care band — a substantial contract for the sector. Based on 32,734 valued Health & Social Care tenders in our corpus.
NGHT has had to publish a VEAT notice for the following therapy: Xofigo (Radium 223) Dose.
The reason for the VEAT notice was due to: "There was a palliative treatment called Strontium that could be used for bone pain, however this involved some significant side-effects and hence it has not been used for a number of years.
This new treatment (Radium 223) has been shown to significantly improve overall survival for this group of patients. (ALSYMPCA trial).
Currently these patients are either sent elsewhere for the same treatment, or they do not receive treatment.
This is the only radiopharmaceutical that has been granted NICE approval for treatment of bone metastasis, and is the only Radium (223) product currently available commercially.
Make the case to bid
Reveal who to approach at Northampton General Hospital N H S Trust, and generate a go-to-market strategy from their news, accounts and people.
Ask me about this tender, the buyer, who wins their work, or whether you should bid.
- OCID
- c5870a3f-91ee-4056-b444-6ea461521a27
- Stage
- contract · Contract
- Source
- Contracts Finder
- Buyer ref
- NGH001-DN220405-82099297/2
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Health & Social Care
Northampton General Hospital N H S Trust’s tender network
Assembling the network…